Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
Dr Noam VanderWalde speaks to ecancer at the SIOG 2019 meeting in Geneva about the use of radiation therapy in older adults.
He explains that due to the localised nature of radiation therapy, it is more likely to be able to be tolerated in patients who have a worse functional status.
Dr VanderWalde highlights the importance for radiation oncologists to become involved with geriatric research and hopes that they can make a big impact.
This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.
Isatuximab, plus bortezomib, lenalidomide, and dexamethasone shows improved PFS in frail NDMM patients
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
ASCO 2024: Lung cancer highlights
Trastuzumab deruxtecan significantly improves PFS In breast cancer patients previously treated with endocrine therapy
ASCO 2024: Lung cancer roundup
Chemotherapy before and after surgery may be new standard treatment for some patients with oesophageal cancer
Osimertinib success in locally advanced EGFR-mutated NSCLC
Adjuvant avelumab versus control does not significantly improve DFS but does improve OS in high-risk TNBC patients
Adagrasib improves on docetaxel in previously treated NSCLC